Profile data is unavailable for this security.
About the company
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is engaged in the development of monoclonal antibodies for the treatment of diseases, such as neuromuscular disorders, cancer, fibrosis, and anemia. The Company's lead product candidate is SRK-015 that is in its pre-clinical stage of development. SRK-015 is a selective inhibitor of the activation of the growth factor myostatin in skeletal muscle. It is used to treat spinal muscular atrophy (SMA). The Company also develops other antibody programs that include TGFÎ²1 and BMP6. The TGFÎ²1 antibody program is focused on the development of antibodies that are specific inhibitors of TGFÎ²1 members. It is channeled for the treatment of diseases, such as tissue and organ fibrosis, bone marrow fibrosis, and other oncologic and hematological disorders.
- Revenue in USD (TTM)15.08m
- Net income in USD-97.08m
- LocationScholar Rock Holding Corp301 BINNEY STREET, 3RD FLOORCAMBRIDGE 02142United StatesUSA
- Phone+1 (857) 259-3860
- Fax+1 (302) 655-5049